公开(公告)号：US20070010575A1

公开(公告)日：2007-01-11

申请号：US11522145

申请日：2006-09-15

Applicant: H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

Inventor： H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

IPC: A61K31/353

CPC classification number: A61K31/352 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K41/0038 ,  A61K41/0057 ,  A61K41/0071 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/153333 ,  Y10T436/19 ,  Y10T436/193333

Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Abstract translation: 描述了新的体内光动力学药物和用于治疗人或动物组织中的这种光动力药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物以包括液体，半固体，固体或气溶胶递送载体的各种制剂生产。

公开(公告)号：US08974363B2

公开(公告)日：2015-03-10

申请号：US11936963

申请日：2007-11-08

Applicant: H. Craig Dees ,  Timothy C. Scott ,  John Smolik ,  Eric A. Wachter ,  Walter G. Fisher

Inventor： H. Craig Dees ,  Timothy C. Scott ,  John Smolik ,  Eric A. Wachter ,  Walter G. Fisher

IPC: A61K31/352 ,  A61K33/14 ,  A61K41/00

CPC classification number: A61K31/352 ,  A61K33/14 ,  A61K41/00 ,  A61K2300/00

Abstract: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid or aerosol delivery vehicles.

Abstract translation: 描述了用于治疗人或动物组织的新的光动力学，局部适用药物和这种光动力药物的某些医学用途，其中这种药物的主要活性成分是卤代呫吨。 卤化呫吨构成了一系列有效的光敏剂，在用可见光波长照射治疗部位时变得光活化。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官的各种病症; 口腔和消化道及相关器官; 泌尿生殖道及相关器官; 呼吸道及相关器官; 各种其他内部或外部组织表面，例如在手术期间暴露的组织表面; 并用于治疗与微生物或寄生虫感染有关的各种病症。 在另一个优选的实施方案中，这种药物是以包括液体，半固体或气溶胶递送载体在内的各种制剂生产的。

公开(公告)号：US08470296B2

公开(公告)日：2013-06-25

申请号：US11715780

申请日：2007-03-08

Applicant: H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

Inventor： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

IPC: A61K51/00

CPC classification number: A61K31/352

Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

公开(公告)号：US20110097280A1

公开(公告)日：2011-04-28

申请号：US12981977

申请日：2010-12-30

Applicant: H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

Inventor： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

IPC: A61K9/12 ,  A61K31/352 ,  A61P35/00 ,  A61P1/04 ,  A61P31/04 ,  A61P31/10 ,  A61P17/00 ,  A61P31/12

CPC classification number: A61K31/352 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K41/0038 ,  A61K41/0057 ,  A61K41/0071 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/153333 ,  Y10T436/19 ,  Y10T436/193333

Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Abstract translation: 描述了新的体内光动力学药物和用于治疗人或动物组织中的这种光动力药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物以包括液体，半固体，固体或气溶胶递送载体的各种制剂生产。

公开(公告)号：US20070078076A1

公开(公告)日：2007-04-05

申请号：US11542533

申请日：2006-10-02

Applicant: H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

Inventor： H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

IPC: A61N5/00 ,  A61K48/00 ,  A61K38/17 ,  A61K31/365

CPC classification number: A61K41/0038 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0057 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y10S436/813 ,  Y10S436/819

Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Abstract translation: 描述了新的体内放射碘化物药物和用于治疗人或动物组织的这种高能光疗药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤化呫吨衍生物。 卤化呫吨构成了一种有效的放射增敏剂，其在用电离辐射照射治疗部位时变得光活化。 在本发明的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官的各种病症， 循环系统和相关器官，头颈部，内分泌和淋巴系统和相关器官，各种其他组织，例如在手术期间暴露的结缔组织和各种组织表面，以及显示微生物或寄生虫感染的各种组织。 ，这些药物是以各种制剂生产的，包括液体，半固体，固体或气溶胶递送载体。

公开(公告)号：US06451597B2

公开(公告)日：2002-09-17

申请号：US09803498

申请日：2001-03-09

Applicant: H. Craig Dees ,  John Smolik

Inventor： H. Craig Dees ,  John Smolik

IPC: C12N502

CPC classification number: C07K14/47 ,  C12N7/00 ,  C12N2760/18451

Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.

公开(公告)号：US07390668B2

公开(公告)日：2008-06-24

申请号：US09799785

申请日：2001-03-06

Applicant: H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

Inventor： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

IPC: G01N33/00

CPC classification number: A61K31/352 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K41/0038 ,  A61K41/0057 ,  A61K41/0071 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/153333 ,  Y10T436/19 ,  Y10T436/193333

Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

公开(公告)号：US20050282889A1

公开(公告)日：2005-12-22

申请号：US11187122

申请日：2005-07-22

Applicant: H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

Inventor： H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

IPC: A61K9/06 ,  A61B17/00 ,  A61B17/22 ,  A61F7/00 ,  A61K9/00 ,  A61K9/08 ,  A61K9/107 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/35 ,  A61K31/352 ,  A61K31/365 ,  A61K41/00 ,  A61K47/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/16 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  A61K47/34 ,  A61K47/42 ,  A61K47/44 ,  A61K47/48 ,  A61K49/00 ,  A61K49/04 ,  A61N5/06 ,  A61P1/00 ,  A61P1/04 ,  A61P5/00 ,  A61P9/00 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P31/00 ,  A61P31/10 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P43/00 ,  C07D311/82 ,  A61K31/353

CPC classification number: A61K31/352 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K41/0038 ,  A61K41/0057 ,  A61K41/0071 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/153333 ,  Y10T436/19 ,  Y10T436/193333

Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Abstract translation: 描述了新的体内光动力学药物和用于治疗人或动物组织中的这种光动力药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物以包括液体，半固体，固体或气溶胶递送载体的各种制剂生产。

公开(公告)号：US20050207976A1

公开(公告)日：2005-09-22

申请号：US11124654

申请日：2005-05-09

Applicant: H. Dees ,  Timothy Scott ,  John Smolik ,  Eric Wachter

Inventor： H. Dees ,  Timothy Scott ,  John Smolik ,  Eric Wachter

IPC: A61N5/10 ,  A61K31/352 ,  A61K41/00 ,  A61K49/04 ,  A61P35/00 ,  A61P43/00 ,  A61K51/00

CPC classification number: A61K41/0038 ,  A61K49/0433 ,  Y10S436/813 ,  Y10S436/819

Abstract: A high energy phototherapeutic agents or radiosensitizer agent comprised of a halogenated xanthene, or an agent that exhibits a preference for concentration in biologically sensitive structures in diseased tissue, and methods of treating and imaging using radiosensitizer agents in diseased tissue.

Abstract translation: 由卤代呫吨或在患病组织中表现出对生物敏感性结构中的浓度偏好的药剂组成的高能光疗剂或放射增敏剂，以及在病变组织中使用放射增敏剂进行治疗和成像的方法。

公开(公告)号：US20050154049A1

公开(公告)日：2005-07-14

申请号：US10999313

申请日：2004-11-30

Applicant: H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

Inventor： H. Dees ,  Timothy Scott ,  Eric Wachter ,  Walter Fisher ,  John Smolik

IPC: A61K9/06 ,  A61B17/00 ,  A61B17/22 ,  A61F7/00 ,  A61K9/00 ,  A61K9/08 ,  A61K9/107 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/35 ,  A61K31/352 ,  A61K31/365 ,  A61K41/00 ,  A61K47/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/16 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  A61K47/34 ,  A61K47/42 ,  A61K47/44 ,  A61K47/48 ,  A61K49/00 ,  A61K49/04 ,  A61N5/06 ,  A61P1/00 ,  A61P1/04 ,  A61P5/00 ,  A61P9/00 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P31/00 ,  A61P31/10 ,  A61P31/12 ,  A61P33/00 ,  A61P35/00 ,  A61P43/00 ,  C07D311/82 ,  A61K31/353 ,  A61N1/30

CPC classification number: A61K31/352 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K41/0038 ,  A61K41/0057 ,  A61K41/0071 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/153333 ,  Y10T436/19 ,  Y10T436/193333

Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.